OncRef

Clinical Trial: NCT05016947

Venetoclax Plus Inotuzumab for B-ALL

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 1

Lead Sponsor:Dana-Farber Cancer Institute
Information Provided By:Dana-Farber Cancer Institute
Last Update Posted:2026-01-29

Study Overview

Brief Summary

This research study is evaluating the safety and efficacy of administering venetoclax and inotuzumab ozogamicin in combination in patients with acute lymphoblastic leukemia (ALL)

The names of the study drugs involved in this study are:

  • Venetoclax
  • Inotuzumab ozogamicin
  • Dexamethasone

Official Title

A Phase 1 Study of Venetoclax in Combination With Inotuzumab Ozogamicin for B-cell Acute Lymphoblastic Leukemia (B-ALL)

Conditions

B-cell Acute Lymphoblastic Leukemia, B-Cell Lymphoma, ALL

Intervention / Treatment

  • Drug: Venetoclax
  • Drug: Dexamethasone
  • Drug: Inotuzumab Ozogamicin

Other Study ID Numbers

  • 21-196

Start Date (Actual)

2021-09-24

Primary Completion Date (Actual)

2023-07-10

Study Completion Date (Estimated)

2026-12-23

Enrollment (Actual)

23

Study Type

Interventional

Phase

Phase 1